'Waterloo': when normal blood cells meet leukemia. Issue 4 (July 2016)

• Record Type: Journal Article
• Authors: Cheng, Hui; Cheng, Tao
• Is Part Of: Current opinion in hematology. Volume 23:Issue 4(2016:Jul.)
• Page Start: 304
• Page End: 310
• Publication Date: 2016-07
• Subjects: hematopoietic stem and progenitor cells -- leukemic cells -- microenvironment -- normal blood cells; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1097/MOH.0000000000000253
• Languages: English
• ISSNs: 1065-6251

Abstract

Abstract : Purpose of review: Mortality and morbidity associated with leukemia are largely due to frequently occurring cytopenias or the dysfunction of normal blood cells in patients. Our knowledge of how normal blood cells degenerate in response to leukemic cell infiltration has been quite limited. This review summarizes recent findings and discusses both extrinsic and intrinsic mechanisms underlying the suppression of normal hematopoiesis in leukemia. Recent findings: Recent studies have shown that leukemic cells are able to remodel the bone marrow niche by secreting specific cytokines or dampening its hematopoietic-supporting functions. In turn, a suitable microenvironment for leukemic cell proliferation but not for normal hematopoietic cell growth is created. Intrinsically, the leukemic condition impairs the normalcy of hematopoietic stem and progenitor cells and alters their signaling networks; consequently, it exhausts hematopoietic progenitor cells and forces stem cells into a more quiescent state, which would allow a reversible suppression of hematopoietic regeneration. The deepened quiescence of hematopoietic stem cells in leukemic marrow was achieved in part via transcription factor Egr3. Summary: These findings provide new insights into the mechanisms underlying hematopoietic suppression in response to leukemic cell outgrowth and offer new strategies to further improve current therapies for leukemias, placing more emphasis on the augmentation of normal hematopoietic regeneration when targeting leukemic cells.